The new suppliers include a cancer-focused biobank in the U.S., which contains a differentiated range of pre-and post-treatment tissue and biofluids across multiple cancer types.
These samples provide rich genetic, treatment, follow-up, and outcome information.
Additionally, iSpecimen has retained a European biobank with a vast urine and blood sample inventory from healthy participants aged 45 to 75, collected with participant health data generated from questionnaires and disease diagnoses.
This biobank contains vital early-onset cancer and cardiovascular disease samples, as well.
iSpecimen offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers with access to patients and specimens needed for medical discovery.
Price Action: ISPC shares are up 21.50% at $2.88 during the market session on the last check Thursday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.